NUVB

Nuvation Bio Inc. is a global oncology company developing small molecule therapeutics targeting validated cancer pathways, with commercial and clinical-stage programs focused on improving safety and efficacy over standard of care treatments. The company's lead approved program is taletrectinib (IBTROZI), a small molecule ROS1 inhibitor approved by the FDA in June 2025 for ROS1-positive non-small cell lung cancer and already approved in Japan and China, with additional Phase 2 and Phase 3 studies ongoing and European regulatory submission planned for 2026. Nuvation Bio also develops novel drug modalities including drug-drug-conjugates to address challenging oncology targets.

Pipeline

Catalyst Calendar